Fabienne Thomas

21PUBLICATIONS
81CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsCancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jun 18, 2026
Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?

|Jan 27, 2026
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Susanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff

|Dec 11, 2025
Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy.

Matthieu Gracia, Sabrina Marsili, Julien Vintejoux

|Jun 19, 2024
Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis.

Manon Launay, Laure Raymond, Jérôme Guitton

|Mar 18, 2024
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.

Anna M Mc Laughlin, Thomas Helland, Fenja Klima

|Sep 28, 2023
Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients.

Ayman Al Saati, Pierre Vande Perre, Julien Plenecassagnes

Pageof 4

Frequent Collaborators

4 joint publications

Etienne Chatelut

3 joint publications

Félicien Le Louedec

3 joint publications

Mélanie White-Koning

3 joint publications

Manon Launay